Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of MELT-100 (Midazolam/Ketamine) vs IV Midazolam and IV Ketamine in Healthy Volunteers
NCT04767035Phase 1Completed
- Sponsor
- Melt Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midazolam + ketamine in Procedural sedation (PS) (4 arms), sponsored by Melt Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Curve to Last Timepoint at 24 hours. Started Dec 2020; status: completed.
02
Drugs
midazolam + ketamine
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT04767035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767035.